Epigenetic crosstalk: a molecular language in human metabolic disorders.

Fecha de publicación:

Autores de IIS La Fe

Abstract

Technological breakthroughs are emphasizing the impact of epigenetic mechanisms in human health highlighting the importance of a fine-tune orchestration of DNA methylation, micro RNAs, histone modifications, and chromatin structure. Transcriptional regulators sense the concentration of intermediary metabolites associated to a wide variety of biological processes including the long-term imprinting and heritable DNA methylation. Recent epigenetic mechanisms associated with cholesterol and lipid homeostasis have a critical impact in the susceptibility, development and progression of complex diseases such as type 2 diabetes mellitus, non-alcoholic fatty liver, obesity and metabolic syndrome. The heritability of epigenetic states emerge as an additional level of complexity where the extension of somatic as well as inherited epigenetic modifications may require a thoughtful reconsideration in many human diseases related with metabolic disorders.

Datos de la publicación

ISSN/ISSNe:
1945-0516, 1945-0524

Frontiers in bioscience (Scholar edition)  Frontiers in Bioscience

Tipo:
Article
Páginas:
46-57
DOI:
Factor de Impacto:
1,109 SCImago
Cuartil:
Q1 SCImago

Documentos

  • No hay documentos

Métricas

Filiaciones

Filiaciones no disponibles

Proyectos asociados

DESARROLLO DE UN MODELO HEPATOCELULAR HUMANO DIFERENCIADO PARA ESTUDIOS DE METABOLISMO Y POTENCIAL INDUCTOR DE NUEVOS FARMACOS

Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL

SAF2003-09353 . 2003

RED TEMATICA DE INVESTIGACION COOPERATIVA EN CANCER (RTICC)

Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO

RD12/0036/0014 . INSTITUTO DE SALUD CARLOS III . 2013

INNOVATIVE APPROACH FOR SELF-MANAGEMENT AND SOCIAL WELFARE OF CYSTIC FIBROSIS PATIENTS IN EUROPE: DEVELOPMENT, VALIDATION AND IMPLEMENTATION OF A TELEMATICS TOOL. MyCyFAPP

Investigador Principal: CARMEN RIBES KONINCKX

643806_H2020-PHC-2014-single-stage-MyCyFApp . COMISION EUROPEA . 2015

INTEGRATIVE (EPI)GENOMIC AND DRUG TARGET ANALYSIS FOR IDENTIFICATION/VALIDATION OF CLINICALLY VALUABLE BIOMARKERS TO IMPROVE THE POOR OUTCOME OF NON-SMALL CELL LUNG CANCER PATIENTS.

Investigador Principal: JUAN SANDOVAL DEL AMOR

CP13/00055 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2015

Cita

Compartir